Veradermics, Incorporated (MANE) is a publicly traded the market company. As of May 21, 2026, MANE trades at $105.72 with a market cap of $4.19B and a P/E ratio of 0.00. MANE moved +5.43% today. Year to date, MANE is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $32.00 to $117.71. Analyst consensus is strong buy with an average price target of $111.00. Rallies surfaces MANE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Veradermics Raises Funding with 3.35M-Share Offering and Reports Positive Phase 2/3 Results: Veradermics launched a public offering of 3.35 million common shares and pre-funded warrants, with a 30-day option for 502,500 additional shares and a private placement to Suvretta Capital affiliates. The company reported positive topline results from its Phase 2/3 VDPHL01 trial, advancing its oral non-hormonal minoxidil formulation for mild-to-moderate hair loss.
| Metric | Value |
|---|---|
| Price | $105.72 |
| Market Cap | $4.19B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $117.71 |
| 52-Week Low | $32.00 |
| Volume | 15 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
4 analysts cover MANE: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $111.00.